Navigation Links
Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT
Date:8/19/2008

LA JOLLA, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that its CEO, James S. Kuo, M.D., M.B.A. will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day.

The presentation with streaming video and PowerPoint will be webcast live and archived on Noble Financial's conference website at http://www.noblemadmax.com. Participants should register at least 10 minutes prior to the start of the presentation to ensure timely access.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
2. Duska Therapeutics Obtains Standard & Poors Listing
3. Arno Therapeutics Announces Second Quarter 2008 Financial Results
4. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
5. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
6. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
Breaking Biology News(10 mins):